Search the Newsreel

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen

Kingfa Science & Technology (India) standalone net profit rises 101.58% in the June 2026 quarter

Absci (NASDAQ:ABSI) Stock Rating Upgraded by Wall Street Zen

Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Lowered by Wall Street Zen

Achieve Life Sciences (NASDAQ:ACHV) recently had its stock rating lowered from "hold" to "strong sell" by Wall Street Zen. Despite this downgrade, the company still holds an average "Buy" rating from other analysts with a consensus target price of $15.00. Achieve Life Sciences, a …

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter

Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Alto Neuroscience (NYSE:ANRO) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a target price of $36.62. Shares opened at $32.14, near their 12-month high, and the company reported a quarterly loss of $0.65 …

Boston Scientific (BSX), What Is Behind The Latest Investor Attention?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Boston Scientific completes multi year buyback and what it means for investors Boston Scientific …

Indogulf Cropsciences Q1FY27 net profit down 38% YoY; EBITDA margin rises to 6%

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com

Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …

Wave Life Sciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043

Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?

In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic …

TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA

TuHURA Biosciences anticipates preliminary results from its IFX-2.0 study, which combines IFX-2.0 with Keytruda for treating deep-seated Merkel Cell Carcinoma (MCC). These results are expected in the first half of 2027. This study represents a key milestone for TuHURA Biosciences in its development of …

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …

Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results

Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …

Boston Scientific (BSX) Stock Looks Cheap On Earnings And Fair Value

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF Value Says Undervalued

Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges …

UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80

UBS has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained its target price at $80. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation …

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

INDA to TWD: iShares MSCI India ETF • Robinhood Token Price in New Taiwan Dollar

This article provides the current conversion rate of iShares MSCI India ETF • Robinhood Token (INDA) to New Taiwan Dollar (TWD), which is NT$1,553.51. It outlines a five-step process on how to buy INDA with TWD, primarily through decentralized exchanges, and includes historical price …

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds

Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted …

Will Absci (NASDAQ:ABSI) Spend Its Cash Wisely?

This article analyzes Absci's financial health, specifically its cash burn rate and cash reserves, to assess its ability to fund operations and future growth. It examines the company's current cash runway, which is estimated to be over two years based on recent expenditures. The …

Alan Fournier's Bold Q2 2026 Move: Exiting Core Scientific Inc for a -4.6% Portfolio Impact

Alan Fournier, founder of Pennant Capital Management, made significant portfolio adjustments in Q2 2026, as revealed in his latest 13F filing. His most notable move was the complete liquidation of his Core Scientific Inc (NASDAQ:CORZ) stake, impacting his portfolio by -4.6%. Conversely, he initiated …

MCDONALDS CORP (MCD) president Anderson Skye details options, PRSUs and stock

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap

An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …

Core Scientific Completes Acquisition of Polaris DS, Advancing Planned Muskogee Expansion to 1.5 GW of Gross Power

Core Scientific has announced the completion of its acquisition of Polaris DS LLC for approximately $444 million in cash, securing about 440 MW of gross power capacity. This acquisition advances Core Scientific's plan to expand its Muskogee campus to 1.5 GW of gross power, …

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …

Valiant Capital discloses 5.3% Core Scientific (CORZ) position in amended 13G

Valiant Capital, along with its entities and Christopher R. Hansen, has disclosed a 5.3% beneficial ownership stake in Core Scientific (CORZ) through an amended Schedule 13G filing. This represents 16,956,009 shares of common stock, based on 321,340,441 shares outstanding as of July 23, 2026. …

Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors

Edwards Lifesciences Corp. (EW) stock fell 1.04% on Friday, closing at $91.60. This underperformance occurred on a generally negative trading day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock experienced its third …

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake